Literature DB >> 1833020

Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells.

D F Schoors1, G P Vauquelin, H De Vos, G Smets, B Velkeniers, L Vanhaelst, A G Dupont.   

Abstract

1. We studied the lactotroph cells of the rat by both in vivo and in vitro pharmacological techniques for the presence of D1-receptors. Both approaches revealed the presence of D2-receptor, stimulated by quinpirole (resulting in an inhibition of prolactin secretion) and blocked by domperidone. 2. Administration of fenoldopam, the most selective D1-receptor agonist currently available, resulted in a dose-dependent decrease of prolactin secretion in vivo (after pretreatment with alpha-methyl-p-tyrosine) and in vitro (cultured pituitary cells). This increase was dose-dependently blocked by the selective D1-receptor antagonist, SCH 23390, and although the effect of fenoldopam was less than that obtained by D2-receptor stimulation, these data suggest that a D1-receptor also controls prolactin secretion. 3. In order to detect the location of these dopamine receptors, autoradiographic studies were performed by use of [3H]-SCH 23390 and [3H]-spiperone as markers for D1- and D2-receptors, respectively. Specific binding sites for [3H]-SCH 23390 were demonstrated. Fenoldopam dose-dependently reduced [3H]-SCH 23390 binding, but had no effect on [3H]-spiperone binding. Immunocytochemical labelling of prolactin cells after incubation with [3H]-SCH 23390 revealed that the granulae and hence, D1 binding sites were present on the lactotroph cells. 4. Radioligand binding studies performed on membranes from anterior pituitary cells revealed the presence of the D2-receptor (54 fmol mg-1 protein) with a Kd of 0.58 nM for [3H]-spiperone, but failed to detect D1-receptors. 5. Finally, we studied the effect of dopamine and of fenoldopam on the adenosine 3':5'-cyclic monophosphate (cyclic AMP) content of anterior pituitary cells. Although cyclic AMP increased upon prostacyclin administration, indicating an intact adenylate cyclase system, fenoldopam failed to increase the cyclic AMP production. 6. It is tempting to speculate that fenoldopam reduces prolactin secretion through interaction with a non-cyclase-linked D1-receptor on the lactotroph cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833020      PMCID: PMC1908193          DOI: 10.1111/j.1476-5381.1991.tb12354.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Absence of D1 dopamine receptors that stimulate prolactin release in the rat pituitary.

Authors:  D Cocchi; S Ingrassia; L Rusconi; I Villa; E E Müller
Journal:  Eur J Pharmacol       Date:  1987-10-27       Impact factor: 4.432

Review 3.  The multiplicity of the D1 dopamine receptor.

Authors:  R B Mailman; D W Schulz; C D Kilts; M H Lewis; H Rollema; S Wyrick
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

Review 4.  5-Hydroxytryptamine receptor subtypes.

Authors:  S J Peroutka
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

5.  The effect of bombesin on basal, alpha-methyl-p-tyrosine, haloperidol, morphine, bremazocine and stress-induced prolactin secretion.

Authors:  P Buydens; J Govaerts; B Velkeniers; E Finné; L Vanhaelst
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

6.  Influence of the dopamine receptor agonists fenoldopam and quinpirole in the rat superior mesenteric vascular bed.

Authors:  A G Dupont; R A Lefebvre; P Vanderniepen
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

7.  Angiotensin II and dopamine modulate both cAMP and inositol phosphate productions in anterior pituitary cells. Involvement in prolactin secretion.

Authors:  A Enjalbert; F Sladeczek; G Guillon; P Bertrand; C Shu; J Epelbaum; A Garcia-Sainz; S Jard; C Lombard; C Kordon
Journal:  J Biol Chem       Date:  1986-03-25       Impact factor: 5.157

8.  The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase.

Authors:  C C Felder; P A Jose; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

9.  Absence of [3H]SCH 23390 specific binding sites in anterior pituitary: dissociation from effects on prolactin secretion.

Authors:  A C Rovescalli; N Brunello; A Monopoli; E Ongini; G Racagni
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

10.  D1 dopamine receptors in human putamen, frontal cortex and calf retina: differences in guanine nucleotide regulation of agonist binding and adenylate cyclase stimulation.

Authors:  J De Keyser; R Dierckx; P Vanderheyden; G Ebinger; G Vauquelin
Journal:  Brain Res       Date:  1988-03-08       Impact factor: 3.252

View more
  8 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

2.  Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.

Authors:  A M Deveney; J L Waddington
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

3.  Roles of dopaminergic d(1) and d(2) receptors in catecholamine release from the rat adrenal medulla.

Authors:  Young Joo Baek; Yoo Seong Seo; Dong Yoon Lim
Journal:  Korean J Physiol Pharmacol       Date:  2008-02-28       Impact factor: 2.016

4.  Atypical SCH23390 binding sites are present on bovine adrenal medullary membranes.

Authors:  M K Dahmer; S E Senogles
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

5.  Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists.

Authors:  Sedat Ava; Leyla Hazar; Mine Karahan; Seyfettin Erdem; Mehmet Emin Dursun; Zafer Pekkolay; Uğur Keklikçi
Journal:  Neuroophthalmology       Date:  2022-01-25

6.  The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213.

Authors:  S A Daly; J L Waddington
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

7.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

8.  The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.